A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer
Status:
Withdrawn
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oromucosal
dose of Sativex in subjects with advanced cancer currently on background Step III opioid
therapy.